Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 25;13:849515. doi: 10.3389/fimmu.2022.849515

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Chentoufi, Dhanushkodi, Srivastava, Prakash, Coulon, Zayou, Vahed, Chentoufi, Hormi-Carver and BenMohamed

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Schematic of Prime-Pull-Keep Therapeutic Vaccine (PPK Vaccine). The PPK vaccine is designed to boost Neutralizing IgG/IgA antibodies (Abs) and boost the number and function of antiviral CD4⁺ and CD8⁺ T_RM cells within the cervico genital muco-cutaneous [CGMC, (1)] and dorsal root ganglia [DRG (2)] tissues. The PPK vaccine is expected to help STOP the virus reactivation from latently infected DRG, virus shedding and virus replication in CGMC, thus curing or reducing recurrent genital herpes disease. *, represent virus.

HHS Vulnerability Disclosure